Avanafil
| 220px | |
| Avanafil
| |
| Systematic (IUPAC) name | |
| 4-[(3-Chloro-4-methoxybenzyl)amino]-2-
[2-(hydroxymethyl)-1-pyrrolidinyl]-N- (2-pyrimidinylmethyl)-5-pyrimidinecarboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C23H26ClN7O3 |
| Mol. mass | 483.951 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Avanafil | |
|
Articles | |
|---|---|
|
Most recent articles on Avanafil | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Avanafil at Clinical Trials.gov Clinical Trials on Avanafil at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Avanafil
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Directions to Hospitals Treating Avanafil Risk calculators and risk factors for Avanafil
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Avanafil | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Avanafil is a PDE5 inhibitor being developed for erectile dysfunction.
Selective Phosphodiesterase inhibitors (C01CE, G04BE) | |
|---|---|
| PDE1 | Vinpocetine |
| PDE2 | EHNA |
| PDE3 | Amrinone, Bucladesine, Enoximone, Milrinone |
| PDE4 | Etazolate, HT-0712, Ibudilast, Mesembrine, Rolipram |
| PDE5 | Avanafil, Sildenafil, Tadalafil, Udenafil, Vardenafil |
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies